表紙
市場調查報告書

LBP (活生物製劑) 與Micro biome (微生物群) 的委託生產市場:2020年∼2030年

Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030

出版商 ROOTS ANALYSIS 商品編碼 929146
出版日期 內容資訊 英文 306 Pages
商品交期: 最快1-2個工作天內
價格
LBP (活生物製劑) 與Micro biome (微生物群) 的委託生產市場:2020年∼2030年 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030
出版日期: 2020年03月31日內容資訊: 英文 306 Pages
簡介

本報告是調查分析微生物群治療的委託生產市場,包含現在的市場現狀與未來的機會,提供完整體系的情報資訊。

考察案例

目錄

第1章 序

第2章 執行摘要

第3章 導論

第4章 市場情勢

  • 章節蓋要
  • 提供微生物群治療委託生產的CMO:企業名單
    • 分析:設立年份
    • 分析:企業規模
    • 分析:經營規模
    • 分析:總公司所在地
    • 分析:提供的服務種類
    • 分析:生產的產品區別
    • 分析:藥物分子類型
    • 分析:所需發酵類型
    • 分析:處方類型
    • 分析:使用的主要包裝類型
    • 分析:生產設施數
    • 分析:生產設施所在地區
    • 分析:規格認證/認證種類
  • 微生物群治療的內部製造商:企業名單
    • 分析:設立年份
    • 分析:企業規模
    • 分析:經營規模
    • 分析:總公司所在地
    • 分析:生產設施所在地區

第5章 企業概論

  • 本章概要
  • 總公司設置在北美的CMO
    • Capsugel
    • Paragon Bioservices
    • UAS Labs
  • 總公司設置在歐洲的CMO
    • Biose
    • Cobra Biologics
    • Cerbios
    • Inpac Probiotics
  • 總公司設置在亞太地區或其他地區的CMO
    • BJP Laboratories

第6章 按照地區區分的能力分析

  • 本章概要
  • 主要的前提與調查方法
  • 按照地區區分的能力分析:北美的微生物群委託生產商
  • 按照地區區分的能力分析:歐洲的微生物群委託生產商
  • 按照地區區分的能力分析:亞太地區或其他地區的微生物群委託生產商
  • 結論

第7章 具有可能性的合作夥伴分析

  • 本章概要
  • 調查範圍與方法
  • 微生物群委託聲產生的潛在戰略合作夥伴
    • 北美的機會
    • 歐洲與亞太地區的機會

第8章 臨床試驗分析

  • 本章概要
  • 調查範圍與方法
  • 臨床試驗分析(業界企業)
    • 分析:試驗登記年份
    • 分析:試驗階段
    • 分析:試驗募集狀況
    • 分析:試驗登記年份與實際狀況
    • 分析:試驗登記年份與登記病患數
    • 分析:研究方法
    • 分析:試驗重點
    • 分析:試驗階段與干預模式種類
    • 分析:贊助/合作商
    • 分析:組織類型
    • 熱門治療領域 - 分析:臨床試驗數與登記年份
    • 按地域區別分析:臨床試驗數
    • 按地域區別分析:試驗募集狀況
  • 臨床試驗分析(非業界企業)
    • 分析:試驗登記年份
    • 分析:試驗階段
    • 分析:試驗募集狀況
    • 分析:試驗登記年份與實際狀況
    • 分析:試驗登記年份與登記病患數
    • 分析:研究方法
    • 分析:試驗重點
    • 分析:試驗階段與干預模式種類
    • 分析:贊助/合作商
    • 分析:組織類型
    • 熱門治療領域 - 分析:臨床試驗數與登記年份
    • 按地域區別分析:臨床試驗數
    • 按地域區別分析:試驗募集狀況

第9章 生產能力分析

  • 本章概要
  • 主要調查前提與方法
  • 微生物群委託製造商:全球的生產能力
    • 分析:企業規模
    • 分析:經營規模
    • 分析:生產設施的地區
  • 結論

第10章 需求分析

  • 本章概要
  • 調查範圍與方法
  • 微生物群委託製造的全球臨床需求
    • 按照地區別分析需求
    • 按照需求階段分析
    • 按照贊助商的需求分析
  • 結論

第11章 生產 vs. 採購的決定構架

第12章 主要製藥公司的微生物群相關倡議

第13章 市場預測

  • 本章概要
  • 預測方法與主要前提條件
  • 微生物群委託生產市場整體
  • 微生物群委託生產市場 - 分佈:生產產品
  • 微生物群委託生產市場 - 分佈:藥劑種類
  • 微生物群委託生產市場 - 分佈:經營規模
  • 微生物群委託生產市場 - 分佈:企業規模
  • 微生物群委託生產市場 - 地理分佈
  • 結論

第14章 結論

第15章 行政考慮

第16章 附錄1:表單數據

第17章 附錄2:企業與組織列表

第18章 附錄3:益生菌輔助品的委託製造商與微生物群委託服務生產商列表

目錄

Example Insights:

Overview:

"I believe that a lot of start-ups have entered the market, however, only a few companies have established their own facilities to manufacture microbiome-based products. This is primarily due to the fact that the cost of establishing an LBP production facility is high, and therefore, requires significant capital investment. As a result, companies have demonstrated preference to outsource manufacturing operations" - Vice President, Sales and Business Development, a US based Small-sized Company.

Harnessing the naturally evolved, medicinal functions of gut bacteria in order to achieve desired clinical outcomes / benefits is the core principle behind the rapidly growing field of microbiome therapeutics. In fact, in recent years, promising insights from microbiome focused research has been the cause of much enthusiasm within the medical science community, offering a novel perspective related to personalized medicine. This particular class of products exists at the interface of naturopathic remedies (considering the active substances that are currently used) and clinically validated interventions, having demonstrated the ability to offer legitimate, quantifiable clinical benefits. Around 200 companies, including both private and public stakeholders, claim to be currently engaged in developing microbiome-based therapies for the treatment of a wide range of diseases. Several large pharmaceutical companies have also demonstrated interest in partnering with early-stage innovators in this domain. Having said that, most such initiatives are either still in the preclinical stages or early phase clinical trials. There are a few microbiome-based product candidates in phase II/III trials, which are anticipated to drive the market's growth in the short-mid term. According to our estimates, the microbiome-based therapeutics market is projected to be worth over USD 2.1 billion by 2030, growing at an annualized rate of over 38%.

Despite the evident increase in interest in this field, manufacturing live microbial therapeutics remains a largely unaddressed area of concern. In fact, experts believe that the lack of sufficient manufacturing capacity is one of the major impediments to the commercialization of such products. Other challenges include absence of the required industry standards related to manufacturing live biotherapeutics, reproducibility (batch-to-batch consistency) related concerns, lack of expertise and infrastructure to handle anaerobic microbial strains, scaling up existing manufacturing protocols, intellectual property related issues (existing patent law prohibits patenting live organisms and naturally occurring materials) and uncertainties related to regulatory review and product approval. Owing to the aforementioned reasons and several others, such as need for specialized facilities, equipment and operational expertise, innovator companies have begun relying on contract manufacturers for their microbiome-related development and production needs. Outsourcing is known to offer several benefits, which include reductions in capital investment, access to larger production capacities, expediting time-to-market, and commercial risk handling and mitigation (to a significant extent). Presently, a number of contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) claim to offer services for manufacturing microbiome-related products. In fact, some have even developed end-to-end capabilities, starting from drug development to regulatory filings, and commercial scale production, in this field.

Scope of the Report:

The "Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030" report features an extensive study of the current landscape and future opportunities related to contract services for microbiome therapeutics. The study features an in-depth analysis, highlighting the capabilities of a diverse set of contract service providers, including CMOs and CDMOs. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of companies offering contract services for manufacturing of microbiome therapeutics, including information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, lyophilization, fill / finish, cell banking, and analytical services), type of product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of drug molecule (small molecules and biologics / live biotherapeutics (LBPs)), type of fermentation (aerobic and anaerobic), type of formulation (solids (tablets / capsules / powders / granules), oral liquids (syrups and solutions), injectables and others), type of primary packaging used (ampoules / vials, blister packing, glass / plastic bottles, pouches / sachets, and others), number and location of manufacturing facilities (country-wise), facility size (if available), as well as their certifications, and company's contact details.
  • A list of companies with in-house manufacturing facilities for microbiome therapeutics along with information on year of establishment, company size, scale of operations (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities (country-wise).
  • Elaborate profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome therapeutics at both clinical and commercial scales. Each profile features a brief overview of the company, microbiome-related service portfolio, information on microbiome manufacturing facilities (if available), and recent developments and an informed future outlook.
  • An assessment of microbiome contract manufacturing capability in different regions, based on a number of relevant parameters, such as number of CMOs, number of completed / active / planned clinical trials, number of patients enrolled, number of manufacturing facilities, number of companies offering API / FDF manufacturing, number of companies having capabilities for preclinical / clinical / commercial manufacturing, number of companies dedicated to aerobic / anaerobic fermentation, installed manufacturing capacity, and number of in-house players.
  • A list of nearly 50 microbiome-focused drug developers that are anticipated to partner with contract manufacturers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account the company's size and its experience in this field), company's pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and the availability of in-house manufacturing capabilities.
  • A detailed clinical trial analysis of more than 150 completed, ongoing and planned studies of various microbiome therapeutics sponsored by both industry and non-industry players; it highlights prevalent trends across various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, trial recruitment status, study design and trial focus, highlighting leading sponsors (in terms of number of trials conducted), type of organization, popular therapeutic areas, and regional distribution of trials.
  • An estimate of the overall, installed capacity for manufacturing of microbiome therapeutics, taking into consideration the capabilities of various stakeholders, based on data gathered via secondary and primary research; it presents the distribution of available capacity in terms of quantity of microbiome therapeutics produced (in liters, per year), across important market segments, such as company size (small-sized, mid-sized and large companies), scale of operation (clinical and commercial), and key geographical regions (North America, Europe and Asia-Pacific and rest of the world).
  • An informed estimate of the annual clinical demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A review of the varied microbiome-focused initiatives of big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the microbiome therapeutics contract manufacturing market. Based on multiple parameters, such as projected growth of the overall microbiome therapeutics market, cost of goods sold and direct manufacturing costs, we developed informed estimates describing the financial evolution of the market, over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of product manufactured (API and FDF), [B] type of formulation (solids, oral liquids, injectables and others), [C] company size (small-sized, mid-sized and large), [D] scale of operation (clinical and commercial), and [E] key geographical regions, covering North America, Europe, Asia-Pacific, and rest of the world. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study was influenced by inputs solicited via a survey and discussions held with multiple senior stakeholders in the industry. The report features detailed transcripts of discussions held with the following individuals:

  • Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)
  • Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals)
  • Assaf Oron (Chief Business Officer, BiomX)
  • Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies)
  • Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)
  • JP Benya (Vice President, Business Development, Assembly Biosciences)
  • Rob van Dijk (Business Development Manager, Wacker Biotech)
  • Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading CMOs offering microbiome contract manufacturing services, across the world?
  • What are the key challenges faced by microbiome contract manufacturers?
  • Who are the most likely partners (microbiome-based live biotherapeutic drug developers) for microbiome contract manufacturers?
  • What is the annual clinical demand for microbiome-based live biotherapeutic products?
  • What is the current, installed contract manufacturing capacity for live biotherapeutics?
  • What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision in this field?
  • What are the various initiatives undertaken by big pharma players in this domain?
  • What percentage of live biotherapeutics manufacturing operations are outsourced to service providers?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to live biotherapeutics manufacturing?

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the microbiome therapeutics contract manufacturing market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to the human microbiome, along with information on the various types of microbiome therapeutics. It also features an elaborate discussion on the functions of the microbiota, emphasizing on the key insights generated from the Human Microbiome Project (HMP). Further, the chapter also includes a description of the various steps that are involved in the manufacturing of microbiome therapeutics. In addition, it highlights the challenges associated with manufacturing such products and the growing need for outsourcing in this domain. Finally, it provides a list of key factors that need to be considered by innovator companies while selecting a CMO partner.

Chapter 4 provides an overview of the microbiome contract manufacturing landscape. It includes information on over 25 contract manufacturers that claim to offer microbiome therapeutics manufacturing services. In addition, it features an in-depth analysis of these companies, based on a number of parameters, such as on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, lyophilization, fill / finish, cell banking, and analytical services), type of product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of drug molecule (small molecules and biologics / live biotherapeutics (LBPs)), type of fermentation (aerobic and anaerobic), type of formulation (solids (tablets / capsules / powders / granules), oral liquids (syrups and solutions), injectables and others), type of primary packaging used (ampoules / vials, blister packing, glass / plastic bottles, pouches / sachets, and others), number and location of manufacturing facilities (country-wise), facility size (if available), as well as their certifications, and company's contact details. A list of companies with in-house manufacturing facilities for microbiome therapeutics along with information on year of establishment, company size, scale of operations (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities (country-wise).

Chapter 5 includes detailed profiles of key industry players (large and mid-sized companies established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome therapeutics at both clinical and commercial scales. Each profile features a brief overview of the company, microbiome-related service portfolio, information on microbiome manufacturing facilities (if available), and recent developments and an informed future outlook

Chapter 6 features an informed assessment of microbiome contract manufacturing capability in different regions, based on a number of relevant parameters, such as number of CMOs, number of completed / active / planned clinical trials, number of patients enrolled, number of manufacturing facilities, number of companies offering API / FDF manufacturing, number of companies having capabilities for preclinical / clinical / / commercial manufacturing, number of companies dedicated to aerobic / anaerobic fermentation, installed manufacturing capacity, and number of in-house players.

Chapter 7 features a list of nearly 50 microbiome-focused drug developers that are anticipated to partner with contract manufacturers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account a company's size and its experience in this field), company's pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and the availability of in-house manufacturing capabilities.

Chapter 8 provides a detailed clinical trial analysis of more than 150 completed, ongoing and planned studies of various microbiome therapeutics sponsored by both industry and non-industry players; it highlights prevalent trends across various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, trial recruitment status, study design and trial focus, highlighting leading sponsors (in terms of number of trials conducted), type of organization, popular therapeutic areas, and regional distribution of trials.

Chapter 9 features an estimate of the overall, installed capacity for manufacturing of microbiome therapeutics, taking into consideration the capabilities of various stakeholders, based on data gathered via secondary and primary research; it presents the distribution of available capacity in terms of quantity of microbiome therapeutics produced (in liters, per year), across important market segments, such as company size (small-sized, mid-sized and large companies), scale of operation (clinical and commercial), and key geographical regions (North America, Europe and Asia-Pacific and rest of the world).

Chapter 10 features an informed estimate of the annual clinical demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.

Chapter 11 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

Chapter 12 a review of the varied microbiome-focused initiatives of big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.

Chapter 13 features an elaborate market forecast analysis, highlighting the likely growth of microbiome contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of product manufactured (API and FDF), B] type of formulation (solids, oral liquids, injectables and others), [C] company size ( small-sized, mid-sized and large), [D] scale of operation (clinical and commercial), and [E] key geographical regions, covering North America, Europe, Asia-Pacific, and rest of the world. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter 14 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 15 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic), Gaurav Kaushik (Managing Director and Chief Executive Officer, Meteoric Biopharmaceuticals), Assaf Oron (Chief Business Officer, BiomX), Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies), Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories), JP Benya (Vice President, Business Development, Assembly Biosciences), Rob van Dijk (Business Development Manager, Wacker Biotech), and Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical).

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

Chapter 18 is an appendix, which contains the list of companies that claim to offer contract manufacturing for probiotic supplements and microbial strains.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Concept of Human Microbiota and Microbiome
  • 3.3. Overview of Gut Flora
    • 3.2.3. Role of Gut Flora in Healthy Individuals
    • 3.2.4. Factors Affecting Human Gut Flora
  • 3.4. The Human Microbiome Project (HMP)
  • 3.5. Overview of Microbiome Therapies
    • 3.5.1. Types of Microbiome Therapies
      • 3.5.1.1. Probiotics
      • 3.5.1.2. Prebiotics
    • 3.5.2. Applications of Microbiome Therapies
    • 3.5.3. Microbiome Therapies Supply Chain
  • 3.6. Microbiome-based Product Manufacturing
    • 3.6.1. Key Steps Involved
    • 3.6.2. Associated Challenges
    • 3.6.3. Role of Contract Manufacturing Organizations (CMOs)
    • 3.6.4. Demand for Contract Manufacturing Services
  • 3.7. Key Considerations for Selecting a Suitable CMO Partner

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. CMOs Offering Contract Manufacturing for Microbiome Therapeutics: List of Companies
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Scale of Operation
    • 4.2.4. Analysis by Location of Headquarters
    • 4.2.5. Analysis by Type of Service Offered
    • 4.2.6. Analysis by Type of Product Manufactured
    • 4.2.7. Analysis by Type of Drug Molecule
    • 4.2.8. Analysis by Type of Fermentation Required
    • 4.2.9. Analysis by Type of Formulation
    • 4.2.10. Analysis by Type of Primary Packaging Used
    • 4.2.11. Analysis by Number of Manufacturing Facilities
    • 4.2.12. Analysis by Location of Manufacturing Facilities
    • 4.2.13. Analysis by Type of Regulatory Certifications / Accreditations
  • 4.3. Microbiome Therapeutics In-House Manufacturers: List of Companies
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Scale of Operation
    • 4.3.4. Analysis by Location of Headquarters
    • 4.3.5. Analysis by Location of Manufacturing Facilities

5. COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. CMOs Headquartered in North America
    • 5.2.1. Capsugel
      • 5.2.1.1. Company Overview
      • 5.2.1.2. Microbiome-Related Service Portfolio
      • 5.2.1.3. Facilities Dedicated to Microbiome Manufacturing
      • 5.2.1.4. Recent Developments and Future Outlook
    • 5.2.2. Paragon Bioservices
      • 5.2.2.1. Company Overview
      • 5.2.2.2. Microbiome-Related Service Portfolio
      • 5.2.2.3. Facilities Dedicated to Microbiome Manufacturing
      • 5.2.2.4. Recent Developments and Future Outlook
    • 5.2.3. UAS Labs
      • 5.2.3.1. Company Overview
      • 5.2.3.2. Microbiome-Related Service Portfolio
      • 5.2.3.3. Facilities Dedicated to Microbiome Manufacturing
      • 5.2.3.4. Recent Developments and Future Outlook
  • 5.3. CMOs Headquartered in Europe
    • 5.3.1. Biose
      • 5.3.1.1. Company Overview
      • 5.3.1.2. Microbiome-Related Service Portfolio
      • 5.3.1.3. Facilities Dedicated to Microbiome Manufacturing
      • 5.3.1.4. Recent Developments and Future Outlook
    • 5.3.2. Cobra Biologics
      • 5.3.2.1. Company Overview
      • 5.3.2.2. Financial Information
      • 5.3.2.3. Microbiome-Related Service Portfolio
      • 5.3.2.4. Facilities Dedicated to Microbiome Manufacturing
      • 5.3.2.5. Recent Developments and Future Outlook
    • 5.3.3. Cerbios
      • 5.3.3.1. Company Overview
      • 5.3.3.2. Microbiome-Related Service Portfolio
      • 5.3.3.3. Facilities Dedicated to Microbiome Manufacturing
      • 5.3.3.4. Recent Developments and Future Outlook
    • 5.3.4. Inpac Probiotics
      • 5.3.4.1. Company Overview
      • 5.3.4.2. Microbiome-Related Service Portfolio
      • 5.3.4.3. Facilities Dedicated to Microbiome Manufacturing
  • 5.4. CMOs Headquartered in Asia-Pacific and Rest of the World
    • 5.4.1. BJP Laboratories
      • 5.4.1.1. Company Overview
      • 5.4.1.2. Microbiome-Related Service Portfolio
      • 5.4.1.3. Facilities Dedicated to Microbiome Manufacturing

6. REGIONAL CAPABILITY ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Key Assumptions and Methodology
  • 6.3. Regional Capability Analysis: Microbiome Contract Manufacturers in North America
  • 6.4. Regional Capability Analysis: Microbiome Contract Manufacturers in Europe
  • 6.5. Regional Capability Analysis: Microbiome Contract Manufacturers in Asia-Pacific and Rest of the World
  • 6.6. Concluding Remarks

7. LIKELY PARTNER ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Potential Strategic Partners for Microbiome Contract Manufacturers
    • 7.3.1. Opportunities in North America
    • 7.3.2. Opportunities in Europe and Asia-Pacific

8. CLINICAL TRIAL ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Clinical Trial Analysis (Industry Players)
    • 8.3.1. Analysis by Trial Registration Year
    • 8.3.2. Analysis by Trial Phase
    • 8.3.3. Analysis by Trial Recruitment Status
    • 8.3.4. Analysis by Trial Registration Year and Recruitment Status
    • 8.3.5. Analysis by Trial Registration Year and Number of Patients Enrolled
    • 8.3.6. Analysis by Study Design
    • 8.3.7. Analysis by Trial Focus
    • 8.3.8. Analysis by Trial Phase and Type of Intervention Model
    • 8.3.9. Analysis by Sponsor / Collaborator
    • 8.3.10. Analysis by Type of Organization
    • 8.3.11. Popular Therapeutic Areas: Analysis by Number of Clinical Trials and Registration Year
    • 8.3.12. Geographical Analysis by Number of Clinical Trials
    • 8.3.13. Geographical Analysis by Trial Recruitment Status
  • 8.4. Clinical Trial Analysis (Non-Industry Players)
    • 8.4.1. Analysis by Trial Registration Year
    • 8.4.2. Analysis by Trial Phase
    • 8.4.3. Analysis by Trial Recruitment Status
    • 8.4.4. Analysis by Trial Registration Year and Recruitment Status
    • 8.4.5. Analysis by Trial Registration Year and Number of Patients Enrolled
    • 8.4.6. Analysis by Study Design
    • 8.4.7. Analysis by Trial Focus
    • 8.4.8. Analysis by Trial Phase and Type of Intervention Model
    • 8.4.9. Analysis by Sponsor / Collaborator
    • 8.4.10. Analysis by Type of Organization
    • 8.4.11. Popular Therapeutic Areas: Analysis by Number of Clinical Trials and Registration Year
    • 8.4.12. Geographical Analysis by Number of Clinical Trials
    • 8.4.13. Geographical Analysis by Trial Recruitment Status

9. CAPACITY ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Key Assumptions and Methodology
  • 9.3. Microbiome Contract Manufacturers: Global Production Capacity
    • 9.3.1. Analysis by Company Size
      • 9.3.1.1. Overall Production Capacity of Small-sized Companies
      • 9.3.1.2. Overall Production Capacity of Mid-sized Companies
      • 9.3.1.3. Overall Production Capacity of Large Companies
    • 9.3.2. Analysis by Scale of Operation
      • 9.3.2.1. Overall Clinical Scale Production Capacity
      • 9.3.2.2. Overall Commercial Scale Production Capacity
    • 9.3.3. Analysis by Location of Manufacturing Facility
      • 9.3.3.1. Overall Production Capacity in North America
      • 9.3.3.2. Overall Production Capacity in Europe
      • 9.3.3.3. Overall Production Capacity in Asia-Pacific and Rest of the World
  • 9.4. Concluding Remarks

10. DEMAND ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Global Clinical Demand for Microbiome Contract Manufacturing
    • 10.3.1. Geographical Analysis of Demand
      • 10.3.1.1. Clinical Demand in North America
      • 10.3.1.2. Clinical Demand in Europe
      • 10.3.1.3. Clinical Demand in Asia-Pacific and Rest of the World
    • 10.3.2. Phase-Wise Analysis of Demand
      • 10.3.2.1. Clinical Demand in Phase I
      • 10.3.2.2. Clinical Demand in Phase II
      • 10.3.2.3. Clinical Demand in Phase III
    • 10.3.3. Sponsor Wise Analysis of Demand
      • 10.3.2.1. Clinical Demand for Industry Sponsors
      • 10.3.2.2. Clinical Demand for Non-Industry Sponsors
  • 10.4 Concluding Remarks

11. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

  • 11.1. Chapter Overview
  • 11.2. Make versus Buy Decision Making: Assumptions and Parameter Definitions
    • 11.2.1. Scenario 1: High Value Addition / Low Complexity
    • 11.2.1. Scenario 2: High Value Addition / High Complexity
    • 11.2.1. Scenario 3: Low Value Addition / Low Complexity
    • 11.2.1. Scenario 4: Low Value Addition / High Complexity
  • 11.3. Contract Manufacturer's Perspective
  • 11.4. Concluding Remarks

12. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. Initiatives of Big Pharmaceutical Players
    • 12.3.1. Analysis by Portfolio Diversity
    • 12.3.2. Analysis by Phase of Development
    • 12.3.3. Analysis by Type of Therapeutic
    • 12.3.4. Analysis by Type of Drug Molecule
    • 12.3.5. Heat Map: Analysis by Target Therapeutic Areas
  • 12.4. Benchmark Analysis of Big Pharmaceutical Players
    • 12.4.1. Spider Web Analysis: Company A
    • 12.4.2. Spider Web Analysis: Company B
    • 12.4.3. Spider Web Analysis: Company C
    • 12.4.4. Spider Web Analysis: Company D
    • 12.4.5. Spider Web Analysis: Company E
    • 12.4.6. Spider Web Analysis: Company F
    • 12.4.7. Spider Web Analysis: Company G
    • 12.4.8. Spider Web Analysis: Company H
    • 12.4.9. Spider Web Analysis: Company I
    • 12.4.10. Spider Web Analysis: Company J
    • 12.4.11. Spider Web Analysis: Company K
  • 12.5. Concluding Remarks

13. MARKET FORECAST

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology and Key Assumptions
  • 13.3. Overall Microbiome Contract Manufacturing Market, 2020-2030
  • 13.4 Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Product Manufactured
    • 13.4.1. Microbiome Contract Manufacturing Market for APIs, 2020-2030
    • 13.4.2. Microbiome Contract Manufacturing Market for FDFs, 2020-2030
  • 13.5. Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Type of Formulation
    • 13.5.1. Microbiome Contract Manufacturing Market for Solid Formulations, 2020-2030
    • 13.5.2. Microbiome Contract Manufacturing Market for Oral Liquids, 2020-2030
    • 13.5.3. Microbiome Contract Manufacturing Market for Injectables, 2020-2030
    • 13.5.4. Microbiome Contract Manufacturing Market for Others, 2020-2030
  • 13.6. Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
    • 13.6.1. Microbiome Contract Manufacturing Market for Clinical Scale Operations, 2020-2030
    • 13.6.2. Microbiome Contract Manufacturing Market for Commercial Scale Operations, 2020-2030
  • 13.7. Microbiome Contract Manufacturing Market, 2020-2030: Distribution by Company Size
    • 13.7.1. Microbiome Contract Manufacturing Market for Small-sized Companies, 2020-2030
    • 13.7.2. Microbiome Contract Manufacturing Market for Mid-sized Companies, 2020-2030
    • 13.7.3. Microbiome Contract Manufacturing Market for Large Companies, 2020-2030
  • 13.8. Microbiome Contract Manufacturing Market, 2020-2030: Geographical Distribution
    • 13.8.1. Microbiome Contract Manufacturing Market in North America, 2020-2030
    • 13.8.2. Microbiome Contract Manufacturing Market in Europe, 2020-2030
    • 13.8.3. Microbiome Contract Manufacturing Market in Asia-Pacific and Rest of the World, 2020-2030
  • 13.9. Concluding Remarks

14. CONCLUSION

  • 14.1. Chapter Overview
  • 14.2. Key Takeaways

15. EXECUTIVE INSIGHTS

  • 15.1. Chapter Overview
  • 15.2. S-Biomedic
    • 15.2.1. Company Snapshot
    • 15.2.2. Interview Transcript: Veronika Oudova, Co-founder and Chief Executive Officer
  • 15.3. Meteoric Biopharmaceuticals
    • 15.3.1. Company Snapshot
    • 15.3.2. Interview Transcript: Gaurav Kaushik, Managing Director and Chief Executive Officer
  • 15.4. BiomX
    • 15.4.1. Company Snapshot
    • 15.4.2. Interview Transcript: Assaf Oron, Chief Business Officer
  • 15.5. Universal Stabilization Technologies
    • 15.5.1 Company Snapshot
    • 15.5.2. Interview Transcript: Alexander Segal, Vice President, Business Development
  • 15.6. List Biological Laboratories
    • 15.6.1. Company Snapshot
    • 15.6.2. Interview Transcript: Debbie Pinkston, Vice President, Sales and Business Development
  • 15.7. Assembly Biosciences
    • 15.7.1. Company Snapshot
    • 15.7.2. Interview Transcript: JP Benya, Vice President, Business Development
  • 15.8. Wacker Biotech
    • 15.8.1 Company Snapshot
    • 15.8.2. Interview Transcript: Rob van Dijk, Business Development Manager
  • 15.9. Chung Mei Pharmaceutical
    • 15.9.1. Company Snapshot
    • 15.9.2. Interview Transcript: Alexander Lin, Associate General Manager

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

18. APPENDIX III: LIST OF PROBIOTIC SUPPLEMENT CONTRACT MANUFACTURERS AND MICROBIAL CONTACT SERVICE PROVIDERS

List Of Figures

  • Figure 3.1 Benefits of the Human Microbiota
  • Figure 3.2 Factors Affecting Gut Flora
  • Figure 3.3 Human Microbiome Project: Key Achievements
  • Figure 3.4 Microbiome Therapies: Design Approaches
  • Figure 3.5 Types of Microbiome Therapies
  • Figure 3.6 Probiotic Drugs: Overview of Beneficial Bacterial Strains
  • Figure 3.7 Microbiome Therapies: Potential Application Areas
  • Figure 3.8 Key Steps Involved in Microbiome Therapeutics Supply Chain
  • Figure 3.9 Key Steps Involved in Microbiome Therapeutics Manufacturing
  • Figure 3.10 Key Challenges in Manufacturing of Microbiome Therapeutics
  • Figure 3.11 Key Strategies to Increase Efficiency of Manufacturing Microbiome Therapeutics
  • Figure 3.12 Microbiome Manufacturing Industry Survey (December 2018): Distribution by Respondent Particulars
  • Figure 3.13 Microbiome Manufacturing Industry Survey (December 2018): Distribution by Manufacturing Preference
  • Figure 4.1 Microbiome Therapeutics Contract Manufacturers: Distribution by Year of Establishment
  • Figure 4.2 Microbiome Therapeutics Contract Manufacturers: Distribution by Company Size
  • Figure 4.3 Microbiome Therapeutics Contract Manufacturers: Distribution by Scale of Operation
  • Figure 4.4 Microbiome Therapeutics Contract Manufacturers: Distribution by Location of Headquarters
  • Figure 4.5 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Service Offered
  • Figure 4.6 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Product Manufactured
  • Figure 4.7 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Drug Molecule
  • Figure 4.8 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Fermentation Required
  • Figure 4.9 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Formulation
  • Figure 4.10 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Primary Packaging Used
  • Figure 4.11 Microbiome Therapeutics Contract Manufacturers: Distribution by Number of Manufacturing Facilities
  • Figure 4.12 Microbiome Therapeutics Contract Manufacturers: Distribution by Location of Manufacturing Facilities
  • Figure 4.13 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Regulatory Certifications / Accreditations
  • Figure 4.14 Microbiome Therapeutics In-House Manufacturers: Distribution by Year of Establishment
  • Figure 4.15 Microbiome Therapeutics In-House Manufacturers: Distribution by Company Size
  • Figure 4.16 Microbiome Therapeutics In-House Manufacturers: Distribution by Scale of Operation
  • Figure 4.17 Microbiome Therapeutics In-House Manufacturers: Distribution by Location of Headquarters
  • Figure 4.18 Microbiome Therapeutics In-House Manufacturers: Distribution by Location of Manufacturing Facilities
  • Figure 5.1 Capsugel: Microbiome-Related Service Portfolio
  • Figure 5.2 Paragon Bioservices: Microbiome-Related Service Portfolio
  • Figure 5.3 UAS Labs: Microbiome-Related Service Portfolio
  • Figure 5.4 Biose: Microbiome-Related Service Portfolio
  • Figure 5.5 Cerbios: Microbiome-Related Service Portfolio
  • Figure 5.6 Cobra Biologics: Microbiome-Related Service Portfolio
  • Figure 5.7 Inpac Probiotics: Microbiome-Related Service Portfolio
  • Figure 5.8 BJP Laboratories: Microbiome-Related Service Portfolio
  • Figure 6.1 Regional Capability Analysis: Microbiome Contract Manufacturers in North America
  • Figure 6.2 Regional Capability Analysis: Microbiome Contract Manufacturers in Europe
  • Figure 6.3 Regional Capability Analysis: Microbiome Contract Manufacturers in Asia-Pacific and Rest of the World
  • Figure 6.4 Regional Capability Analysis: Comparison of Capabilities across Different Regions
  • Figure 8.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 8.2 Clinical Trial Analysis for Industry Players: Distribution by Trial Registration Year
  • Figure 8.3 Clinical Trial Analysis for Industry Players: Distribution by Trial Phase
  • Figure 8.4 Clinical Trial Analysis for Industry Players: Distribution by Trial Recruitment Status
  • Figure 8.5 Clinical Trial Analysis for Industry Players: Distribution by Trial Registration Year and Recruitment Status
  • Figure 8.6 Clinical Trial Analysis for Industry Players: Distribution by Trial Registration Year and Number of Patients Enrolled
  • Figure 8.7 Clinical Trial Analysis for Industry Players: Distribution by Study Design
  • Figure 8.8 Clinical Trial Analysis for Industry Players: Distribution by Trial Focus
  • Figure 8.9 Clinical Trial Analysis for Industry Players: Distribution by Trial Phase and Type of Intervention Model
  • Figure 8.10 Clinical Trial Analysis for Industry Players: Distribution by Sponsor / Collaborator
  • Figure 8.11 Clinical Trial Analysis for Industry Players: Distribution by Type of Organization
  • Figure 8.12 Clinical Trial Analysis for Industry Players: Year wise trend in Number of Clinical Trials for Popular Therapeutic Areas
  • Figure 8.13 Clinical Trial Analysis for Industry Players: Geographical Distribution by Number of Clinical Trials
  • Figure 8.14 Clinical Trial Analysis for Industry Players: Geographical Distribution by Trial Recruitment Status
  • Figure 8.15 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Registration Year
  • Figure 8.16 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Phase
  • Figure 8.17 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Recruitment Status
  • Figure 8.18 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Registration Year and Recruitment Status
  • Figure 8.19 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Registration Year and Number of Patients Enrolled
  • Figure 8.20 Clinical Trial Analysis for Non-Industry Players: Distribution by Study Design
  • Figure 8.21 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Focus
  • Figure 8.22 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Phase and Type of Intervention Model
  • Figure 8.23 Clinical Trial Analysis for Non-Industry Players: Distribution by Sponsor / Collaborator
  • Figure 8.24 Clinical Trial Analysis for Non-Industry Players: Distribution by Type of Organization
  • Figure 8.25 Clinical Trial Analysis for Non-Industry Players: Year wise trend in Number of Clinical Trials for Popular Therapeutic Areas
  • Figure 8.26 Clinical Trial Analysis for Non-Industry Players: Geographical Distribution by Number of Clinical Trials
  • Figure 8.27 Clinical Trial Analysis for Non-Industry Players: Geographical Distribution by Trial Recruitment Status
  • Figure 9.1 Microbiome Contract Manufacturing Capacity: Distribution by Company Size
  • Figure 9.2 Microbiome Contract Manufacturing Capacity of Small-sized Companies (Kilo Liters)
  • Figure 9.3 Microbiome Contract Manufacturing Capacity of Mid-sized Companies (Kilo Liters)
  • Figure 9.4 Microbiome Contract Manufacturing Capacity of Large Companies (Kilo Liters)
  • Figure 9.5 Microbiome Contract Manufacturing Capacity: Distribution by Scale of Operation
  • Figure 9.6 Clinical Scale Microbiome Contract Manufacturing Capacity (Kilo Liters)
  • Figure 9.7 Commercial Scale Microbiome Contract Manufacturing Capacity (Kilo Liters)
  • Figure 9.8 Microbiome Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
  • Figure 9.9 Microbiome Contract Manufacturing Capacity in North America (Kilo Liters)
  • Figure 9.10 Microbiome Contract Manufacturing Capacity in Europe (Kilo Liters)
  • Figure 9.11 Microbiome Contract Manufacturing Capacity in Asia-Pacific and Rest of the World (Kilo Liters)
  • Figure 10.1 Current Clinical Demand for Microbiome Contract Manufacturing: Scope and Methodology
  • Figure 10.2 Microbiome-based Live Biotherapeutics Pipeline: Distribution by Phase of Development
  • Figure 10.3 Global Clinical Demand for Microbiome Contract Manufacturing, 2020-2030 (Number of Trials Conducted)
  • Figure 10.4 Global Clinical Demand for Microbiome Contract Manufacturing, 2020-2030 (Number of Enrolled Patients)
  • Figure 10.5 Clinical Demand for Microbiome Contract Manufacturing: Distribution by Geography, 2025 and 2030 (Number of Enrolled Patients)
  • Figure 10.6 Current Clinical Demand for Microbiome Contract Manufacturing in North America, 2019 (Number of Enrolled Patients)
  • Figure 10.7 Clinical Demand for Microbiome Contract Manufacturing in North America, 2020-2030 (Number of Enrolled Patients)
  • Figure 10.8 Current Clinical Demand for Microbiome Contract Manufacturing in Europe, 2019 (Number of Enrolled Patients)
  • Figure 10.9 Clinical Demand for Microbiome Contract Manufacturing in Europe, 2020-2030 (Number of Enrolled Patients)
  • Figure 10.10 Current Clinical Demand for Microbiome Contract Manufacturing in Asia-Pacific and Rest of the World, 2019 (Number of Enrolled Patients)
  • Figure 10.11 Clinical Demand for Microbiome Contract Manufacturing in Asia-Pacific and Rest of the World, 2020-2030 (Number of Enrolled Patients)
  • Figure 10.12 Clinical Demand for Microbiome Contract Manufacturing: Distribution by Phase of Development, 2025 and 2030 (Number of Enrolled Patients)
  • Figure 10.13 Clinical Demand for Microbiome Contract Manufacturing in Phase I Trials, 2020-2030 (Number of Enrolled Patients)
  • Figure 10.14 Clinical Demand for Microbiome Contract Manufacturing in Phase II Trials, 2020-2030 (Number of Enrolled Patients)
  • Figure 10.15 Clinical Demand for Microbiome Contract Manufacturing in Phase III Trials, 2020-2030 (Number of Enrolled Patients)
  • Figure 10.16 Clinical Demand for Microbiome Contract Manufacturing: Distribution by Type of Sponsor, 2025 and 2030 (Number of Enrolled Patients)
  • Figure 10.17 Clinical Demand for Microbiome Contract Manufacturing in Industry Sponsored Trials, 2020-2030 (Number of Enrolled Patients)
  • Figure 10.18 Clinical Demand for Microbiome Contract Manufacturing in Non-Industry Sponsored Trials, 2020-2030 (Number of Enrolled Patients)
  • Figure 11.1 Make versus Buy Decision Making Framework
  • Figure 11.2 Make versus Buy Decision Making: Description of Possible Scenarios
  • Figure 11.3 Make versus Buy Thinking: Contract Manufacturers' Perspective
  • Figure 12.1 Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
  • Figure 12.2 Big Pharma Players: Analysis by Portfolio Diversity
  • Figure 12.3 Big Pharma Players: Analysis by Phase of Development
  • Figure 12.4 Big Pharma Players: Analysis by Type of Therapeutic
  • Figure 12.5 Big Pharma Players: Analysis by Type of Drug Molecule
  • Figure 12.6 Big Pharma Players: Analysis by Target Therapeutic Areas
  • Figure 12.7 Spider Web Analysis: Company A
  • Figure 12.8 Spider Web Analysis: Company B
  • Figure 12.9 Spider Web Analysis: Company C
  • Figure 12.10 Spider Web Analysis: Company D
  • Figure 12.11 Spider Web Analysis: Company E
  • Figure 12.12 Spider Web Analysis: Company F
  • Figure 12.13 Spider Web Analysis: Company G
  • Figure 12.14 Spider Web Analysis: Company H
  • Figure 12.15 Spider Web Analysis: Company I
  • Figure 12.16 Spider Web Analysis: Company J
  • Figure 12.17 Spider Web Analysis: Company K
  • Figure 13.1 Commercial Microbiome Contract Manufacturing: Market Forecast Methodology
  • Figure 13.2 Clinical Trial Analysis for Industry Players: Distribution by Type of Sponsor, 2019 (Number of Enrolled Patients)
  • Figure 13.3 Clinical Microbiome Contract Manufacturing: Market Forecast Methodology
  • Figure 13.4 Overall Microbiome Contract Manufacturing Market, 2020-2030 (USD Million)
  • Figure 13.5 Microbiome Contract Manufacturing Market, 2020 and 2030: Distribution by Product Manufactured (USD Million)
  • Figure 13.6 Microbiome Contract Manufacturing Market for APIs, 2020-2030 (USD Million)
  • Figure 13.7 Microbiome Contract Manufacturing Market for FDFs, 2020-2030 (USD Million)
  • Figure 13.8 Microbiome Contract Manufacturing Market: Distribution by Type of Formulation, 2020 and 2030 (USD Million)
  • Figure 13.9 Microbiome Contract Manufacturing Market for Solid Formulations, 2020-2030 (USD Million)
  • Figure 13.10 Microbiome Contract Manufacturing Market for Oral Liquids, 2020-2030 (USD Million)
  • Figure 13.11 Microbiome Contract Manufacturing Market for Injectables, 2020-2030 (USD Million)
  • Figure 13.12 Microbiome Contract Manufacturing Market for Others, 2020-2030 (USD Million)
  • Figure 13.13 Microbiome Contract Manufacturing Market: Distribution by Scale of Operation, 2020 and 2030 (USD Million)
  • Figure 13.14 Microbiome Contract Manufacturing Market for Clinical Scale Operations, 2020-2030 (USD Million)
  • Figure 13.15 Microbiome Contract Manufacturing Market for Commercial Scale Operations, 2020-2030 (USD Million)
  • Figure 13.16 Microbiome Contract Manufacturing Market: Distribution by Company Size, 2020 and 2030 (USD Million)
  • Figure 13.17 Microbiome Contract Manufacturing Market for Small-sized Companies, 2020-2030 (USD Million)
  • Figure 13.18 Microbiome Contract Manufacturing Market for Mid-sized Companies, 2020-2030 (USD Million)
  • Figure 13.19 Microbiome Contract Manufacturing Market for Large Companies, 2020-2030 (USD Million)
  • Figure 13.20 Microbiome Contract Manufacturing Market: Distribution by Geography, 2020 and 2030 (USD Million)
  • Figure 13.21 Microbiome Contract Manufacturing Market in North America, 2020-2030 (USD Million)
  • Figure 13.22 Microbiome Contract Manufacturing Market in Europe, 2020-2030 (USD Million)
  • Figure 13.23 Microbiome Contract Manufacturing Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)
  • Figure 13.24 Microbiome Contract Manufacturing Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)

List Of Tables

  • Table 3.1 Different Types of Microbiota in the Gastrointestinal Tract
  • Table 3.2 Foods Containing Prebiotics
  • Table 3.3 Comparison of Key Factors for the Selection of CMOs: Harvey Ball Analysis
  • Table 4.1 Microbiome Therapeutics Contract Manufacturers: List of Companies
  • Table 4.2 Microbiome Therapeutics Contract Manufacturers: Information on Type of Service Offered
  • Table 4.3 Microbiome Therapeutics Contract Manufacturers: Information on Type of Product Manufactured
  • Table 4.4 Microbiome Therapeutics Contract Manufacturers: Information on Type of Drug Molecule
  • Table 4.5 Microbiome Therapeutics Contract Manufacturers: Information on Type of Fermentation Required
  • Table 4.6 Microbiome Therapeutics Contract Manufacturers: Information on Type of Formulation
  • Table 4.7 Microbiome Therapeutics Contract Manufacturers: Information on Type of Primary Packaging Used
  • Table 4.8 Microbiome Therapeutics Contract Manufacturers: Information on Manufacturing Facilities
  • Table 4.9 Microbiome Therapeutics Contract Manufacturers: Information on Type of Regulatory Certifications / Accreditations
  • Table 4.10 Microbiome Therapeutics Contract Manufacturers: Information on Contact Details
  • Table 4.11 Microbiome Therapeutics In-House Manufacturers: List of Companies
  • Table 4.12 Microbiome Therapeutics In-House Manufacturers: Information on Manufacturing Facilities
  • Table 5.1 Microbiome Contract Manufacturing Organizations: List of Companies Profiled
  • Table 5.2 Capsugel: Recent Developments and Future Outlook
  • Table 5.3 Paragon Bioservices: Recent Developments and Future Outlook
  • Table 5.4 UAS Labs: Recent Developments and Future Outlook
  • Table 5.5 Biose: Recent Developments and Future Outlook
  • Table 5.6 Cobra Biologics: Recent Developments and Future Outlook
  • Table 5.7 Cerbios: Recent Developments and Future Outlook
  • Table 7.1 Likely Partners in North America
  • Table 7.2 Likely Partners in Europe and Asia-Pacific
  • Table 9.1 Microbiome Therapeutics Contract Manufacturers: Average Capacity by Company Size (Sample Data Set)
  • Table 9.2 Microbiome Therapeutics Contract Manufacturers: Total Installed Capacity by Company Size
  • Table 10.1 Clinical Demand for Microbiome Contract Manufacturing: Phase wise Distribution of Average Number of Enrolled Patients
  • Table 12.1 Big Pharma Players: Spider-Web Analysis (Input Data)
  • Table 14.1 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Summary of the Competitive Insights
  • Table 15.1 S-Biomedic: Company Snapshot
  • Table 15.2 Meteoric Biopharmaceuticals: Company Snapshot
  • Table 15.3 BiomX: Company Snapshot
  • Table 15.4 Universal Stabilization Technologies: Company Snapshot
  • Table 15.5 List Biological Laboratories: Company Snapshot
  • Table 15.6 Assembly Biosciences: Company Snapshot
  • Table 15.7 Wacker Biotech: Company Snapshot
  • Table 15.8 Chung Mei Pharmaceutical: Company Snapshot
  • Table 16.1 Survey Respondents (December 2018): Distribution by Respondent Particulars
  • Table 16.2 Survey Respondents (December 2018): Distribution by Manufacturing Preference
  • Table 16.3 Microbiome Therapeutics Contract Manufacturers: Distribution by Year of Establishment
  • Table 16.4 Microbiome Therapeutics Contract Manufacturers: Distribution by Company Size
  • Table 16.5 Microbiome Therapeutics Contract Manufacturers: Distribution by Scale of Operation
  • Table 16.6 Microbiome Therapeutics Contract Manufacturers: Distribution by Location of Headquarters
  • Table 16.7 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Service Offered
  • Table 16.8 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Product Manufactured
  • Table 16.9 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Drug Molecule
  • Table 16.10 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Fermentation Required
  • Table 16.11 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Formulation
  • Table 16.12 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Primary Packaging Used
  • Table 16.13 Microbiome Therapeutics Contract Manufacturers: Distribution by Number of Manufacturing Facilities
  • Table 16.14 Microbiome Therapeutics Contract Manufacturers: Distribution by Location of Manufacturing Facilities
  • Table 16.15 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Regulatory Certifications / Accreditations
  • Table 16.16 Microbiome Therapeutics In-House Manufacturers: Distribution by Year of Establishment
  • Table 16.17 Microbiome Therapeutics In-House Manufacturers: Distribution by Company Size
  • Table 16.18 Microbiome Therapeutics In-House Manufacturers: Distribution by Scale of Operation
  • Table 16.19 Microbiome Therapeutics In-House Manufacturers: Distribution by Location of Headquarters
  • Table 16.20 Microbiome Therapeutics In-House Manufacturers: Distribution by Location of Manugacturing Facilities
  • Table 16.21 Regional Capability Analysis: Microbiome Contract Manufacturers in North America
  • Table 16.22 Regional Capability Analysis: Microbiome Contract Manufacturers in Europe
  • Table 16.23 Regional Capability Analysis: Microbiome Contract Manufacturers in Asia-Pacific and Rest of the World
  • Table 16.24 Clinical Trial Analysis for Industry Players: Distribution by Trial Registration Year
  • Table 16.25 Clinical Trial Analysis for Industry Players: Distribution by Trial Phase
  • Table 16.26 Clinical Trial Analysis for Industry Players: Distribution by Trial Recruitment Status
  • Table 16.27 Clinical Trial Analysis for Industry Players: Distribution by Trial Registration Year and Recruitment Status
  • Table 16.28 Clinical Trial Analysis for Industry Players: Distribution by Trial Registration Year and Number of Patients Enrolled
  • Table 16.29 Clinical Trial Analysis for Industry Players: Distribution by Study Design
  • Table 16.30 Clinical Trial Analysis for Industry Players: Distribution by Trial Phase and Type of Intervention Model
  • Table 16.31 Clinical Trial Analysis for Industry Players: Distribution by Sponsor / Collaborator
  • Table 16.32 Clinical Trial Analysis for Industry Players: Distribution by Type of Organization
  • Table 16.33 Clinical Trial Analysis for Industry Players: Year wise trend in Number of Clinical Trials for Popular Therapeutic Areas
  • Table 16.34 Clinical Trial Analysis for Industry Players: Geographical Distribution by Number of Clinical Trials
  • Table 16.35 Clinical Trial Analysis for Industry Players: Geographical Distribution by Trial Recruitment Status
  • Table 16.36 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Registration Year
  • Table 16.37 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Phase
  • Table 16.38 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Recruitment Status
  • Table 16.39 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Registration Year and Recruitment Status
  • Table 16.40 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Registration Year and Number of Patients Enrolled
  • Table 16.41 Clinical Trial Analysis for Non-Industry Players: Distribution by Study Design
  • Table 16.42 Clinical Trial Analysis for Non-Industry Players: Distribution by Trial Phase and Type of Intervention Model
  • Table 16.43 Clinical Trial Analysis for Non-Industry Players: Distribution by Sponsor / Collaborator
  • Table 16.44 Clinical Trial Analysis for Non-Industry Players: Distribution by Type of Organization
  • Table 16.45 Clinical Trial Analysis for Non-Industry Players: Year wise trend in Number of Clinical Trials for Popular Therapeutic Areas
  • Table 16.46 Clinical Trial Analysis for Non-Industry Players: Geographical Distribution by Number of Clinical Trials
  • Table 16.47 Clinical Trial Analysis for Non-Industry Players: Geographical Distribution by Trial Recruitment Status
  • Table 16.48 Microbiome Contract Manufacturing Capacity: Distribution by Company Size
  • Table 16.49 Microbiome Contract Manufacturing Capacity: Distribution by Scale of Operation
  • Table 16.50 Microbiome Contract Manufacturing Capacity: Distribution by Geography
  • Table 16.51 Microbiome Contract Manufacturing Capacity in North America (Kilo Liters)
  • Table 16.52 Microbiome Contract Manufacturing Capacity in Europe (Kilo Liters)
  • Table 16.53 Microbiome Contract Manufacturing Capacity in Asia-Pacific and Rest of the World (Kilo Liters)
  • Table 16.54 Microbiome-based Live Biotherapeutics Pipeline: Distribution by Phase of Development
  • Table 16.55 Global Clinical Demand for Microbiome Contract Manufacturing, 2020-2030 (Number of Trials Conducted)
  • Table 16.56 Global Clinical Demand for Microbiome Contract Manufacturing, 2020-2030 (Number of Enrolled Patients)
  • Table 16.57 Clinical Demand for Microbiome Contract Manufacturing: Distribution by Geography, 2025 and 2030 (Number of Enrolled Patients)
  • Table 16.58 Clinical Demand for Microbiome Contract Manufacturing in North America, 2020-2030 (Number of Enrolled Patients)
  • Table 16.59 Current Clinical Demand for Microbiome Contract Manufacturing in Europe, 2020-2030 (Number of Enrolled Patients)
  • Table 16.60 Current Clinical Demand for Microbiome Contract Manufacturing in Asia-Pacific and Rest of the World, 2020-2030 (Number of Enrolled Patients)
  • Table 16.61 Clinical Demand for Microbiome Contract Manufacturing: Distribution by Phase of Development, 2025 and 2030 (Number of Enrolled Patients)
  • Table 16.62 Clinical Demand for Microbiome Contract Manufacturing in Phase I Trials, 2020-2030 (Number of Enrolled Patients)
  • Table 16.63 Clinical Demand for Microbiome Contract Manufacturing in Phase II Trials, 2020-2030 (Number of Enrolled Patients)
  • Table 16.64 Clinical Demand for Microbiome Contract Manufacturing in Phase III Trials, 2020-2030 (Number of Enrolled Patients)
  • Table 16.65 Clinical Demand for Microbiome Contract Manufacturing: Distribution by Type of Sponsor, 2025 and 2030 (Number of Enrolled Patients)
  • Table 16.66 Clinical Demand for Microbiome Contract Manufacturing in Industry Sponsored Trials, 2020-2030 (Number of Enrolled Patients)
  • Table 16.67 Clinical Demand for Microbiome Contract Manufacturing in Non-Industry Sponsored Trials, 2020-2030 (Number of Enrolled Patients)
  • Table 16.68 Clinical Trial Analysis for Industry Players: Distribution by Type of Sponsor, 2019 (Number of Enrolled Patients)
  • Table 16.69 Overall Microbiome Contract Manufacturing Market, 2020-2030 (USD Million)
  • Table 16.70 Microbiome Contract Manufacturing Market: Distribution by Product Manufactured, 2020 and 2030 (USD Million)
  • Table 16.71 Microbiome Contract Manufacturing Market for APIs, 2020-2030 (USD Million)
  • Table 16.72 Microbiome Contract Manufacturing Market for FDFs, 2020-2030 (USD Million)
  • Table 16.73 Microbiome Contract Manufacturing Market: Distribution by Type of Formulation, 2020 and 2030 (USD Million)
  • Table 16.74 Microbiome Contract Manufacturing Market for Solid Formulations, 2020-2030 (USD Million)
  • Table 16.75 Microbiome Contract Manufacturing Market for Oral Liquids, 2020-2030 (USD Million)
  • Table 16.76 Microbiome Contract Manufacturing Market for Injectables, 2020-2030 (USD Million)
  • Table 16.77 Microbiome Contract Manufacturing Market for Others, 2020-2030 (USD Million)
  • Table 16.78 Microbiome Contract Manufacturing Market: Distribution by Scale of Operation, 2020 and 2030 (USD Million)
  • Table 16.79 Microbiome Contract Manufacturing Market for Clinical Scale Operations, 2020-2030 (USD Million)
  • Table 16.80 Microbiome Contract Manufacturing Market for Commercial Scale Operations, 2020-2030 (USD Million)
  • Table 16.81 Microbiome Contract Manufacturing Market: Distribution by Company Size, 2020 and 2030 (USD Million)
  • Table 16.82 Microbiome Contract Manufacturing Market for Small-sized Companies, 2020-2030 (USD Million)
  • Table 16.83 Microbiome Contract Manufacturing Market for Mid-sized Companies, 2020-2030 (USD Million)
  • Table 16.84 Microbiome Contract Manufacturing Market for Large Companies, 2020-2030 (USD Million)
  • Table 16.85 Microbiome Contract Manufacturing Market: Distribution by Geography, 2020 and 2030 (USD Million)
  • Table 16.86 Microbiome Contract Manufacturing Market in North America, 2020-2030 (USD Million)
  • Table 16.87 Microbiome Contract Manufacturing Market in Europe, 2020-2030 (USD Million)
  • Table 16.88 Microbiome Contract Manufacturing Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)
  • Table 16.89 Microbiome Contract Manufacturing Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
  • Table 18.1 Probiotic Supplement Contract Manufacturers: List of Companies
  • Table 18.2 Microbial Contract Manufacturers: List of Companies

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 3P Biopharmaceuticals
  • 2. 3SBio
  • 3. 4D Pharma
  • 4. 53Biologics
  • 5. AbbVie
  • 6. AbbVie Contract Manufacturing
  • 7. ABCO Laboratories
  • 8. ABH Pharma
  • 9. AceBiome
  • 10. ActoBio Therapeutics (a subsidiary of Intrexon)
  • 11. Actygea
  • 12. Adare Pharmaceuticals
  • 13. ADM Biopolis
  • 14. ADM Protexin
  • 15. Advanced BioScience Laboratories
  • 16. Advanced Enzymes
  • 17. Affinity Life Sciences
  • 18. AGC Biologics
  • 19. Ajinomoto Bio-Pharma Services
  • 20. Albumedix
  • 21. Aldevron
  • 22. Allergan
  • 23. Allianz Biosciences
  • 24. AMAbiotics
  • 25. AMRI
  • 26. AOBiome Therapeutics
  • 27. APC Microbiome Institute
  • 28. Armata Pharmaceuticals
  • 29. Arranta Bio
  • 30. Assembly Biosciences
  • 31. AST Enzymes
  • 32. AstraZeneca
  • 33. Atlantic Essential Products
  • 34. Aumgene Biosciences
  • 35. AURA Biotechnologies
  • 36. Axcellerate Pharma
  • 37. Axial Biotherapeutics
  • 38. Azitra
  • 39. BacThera
  • 40. Batavia Biosciences
  • 41. Baylor College of Medicine
  • 42. Biena
  • 43. Bifodan
  • 44. Binex
  • 45. Bio Elpida
  • 46. Bio Farma
  • 47. Bio Synergy
  • 48. BioCare Copenhagen
  • 49. BioCell
  • 50. Biocodex
  • 51. BIOFABRI
  • 52. BioGaia
  • 53. Bio-K Plus International
  • 54. Biological E.
  • 55. BioMARC
  • 56. Biomica (a subsidiary of Evogene)
  • 57. BiomX
  • 58. BioProduction by Sekisui
  • 59. biose
  • 60. Biosortia Pharmaceuticals
  • 61. Bio-Synthesis
  • 62. Bio-Technology General
  • 63. BioThrive Sciences
  • 64. BioVectra
  • 65. Biovian
  • 66. BJP Laboratories
  • 67. Bloom Science
  • 68. Blue Turtle Bio Technologies
  • 69. Boehringer Ingelheim BioXcellence
  • 70. Boston Analytical
  • 71. Boston Institute of Biotechnology
  • 72. Boston Medical Center
  • 73. Bristol-Myers Squibb
  • 74. Broad Institute
  • 75. Caelus Health
  • 76. Capsugel
  • 77. Capua BioServices
  • 78. Carbiotix
  • 79. Catalent Biologics
  • 80. Cell Biotech
  • 81. Cerbios-Pharma
  • 82. CEVEC Pharmaceuticals
  • 83. CHAIN Biotechnology
  • 84. Charles River Laboratories
  • 85. ChemPartner Biologics
  • 86. CinnaGen
  • 87. ClostraBio
  • 88. Cobra Biologics
  • 89. Commense (a subsidiary of PureTech Health)
  • 90. Concord Biotech
  • 91. Corden BioChem
  • 92. Creative Biolabs
  • 93. Crown Laboratories
  • 94. Custom Probiotics
  • 95. Cytovance Biologics
  • 96. DANIN International
  • 97. DaVolterra
  • 98. DayTwo
  • 99. Deerland Probiotics & Enzymes
  • 100. DermBiont
  • 101. DuPont
  • 102. EirGenix
  • 103. EKF Life Sciences
  • 104. Elmed
  • 105. Emerge Nutraceuticals
  • 106. Emergent Biosolutions
  • 107. EMF
  • 108. Enteris BioPharma
  • 109. Enterome
  • 110. Etinpro
  • 111. EuBiologics
  • 112. EUCODIS Bioscience
  • 113. Eurogentec
  • 114. Evelo Biosciences
  • 115. Evogene
  • 116. Evonik Health Care
  • 117. EXDEN
  • 118. Exeliom Biosciences
  • 119. Exim Pharma
  • 120. Ferring Pharmaceuticals
  • 121. Finch Therapeutics
  • 122. Food and Agriculture Organization
  • 123. FUJIFILM Diosynth Biotechnologies
  • 124. Ganeden
  • 125. GE Healthcare
  • 126. GenIbet Biopharmaceuticals
  • 127. GENIBIO (a subsidiary of the LARENA and GB ACTION)
  • 128. Genome and Company
  • 129. GI Innovation
  • 130. GSK Contract Manufacturing
  • 131. GTP Technology
  • 132. Gusto Global
  • 133. Holobiome
  • 134. Hong Kong Institute of Biotechnology
  • 135. Igen Biotech
  • 136. ImmuneBiotech
  • 137. Immuron
  • 138. Infact Bacterial Therapeutics
  • 139. Inpac Probiotics
  • 140. Institute for Research in Biomedicine (IRB)
  • 141. Intron Life Sciences (ILS)
  • 142. Ion Labs
  • 143. IVERIC bio
  • 144. J. Craig Venter Institute
  • 145. Jeneil Biotech
  • 146. JLABS
  • 147. Johnson & Johnson
  • 148. JW Nutritional
  • 149. Kaleido Biosciences
  • 150. Kallyope
  • 151. Kanda Biotech
  • 152. Karyotica Biologicals
  • 153. KBI Biopharma
  • 154. Kendy Pharma
  • 155. Kibow Biotech
  • 156. KNect365 Life Sciences
  • 157. LakePharma
  • 158. Lallemand
  • 159. Leadiant Biosciences
  • 160. List Biological Laboratories
  • 161. LNC Therapeutics
  • 162. Locus Biosciences
  • 163. Lonza
  • 164. LUCA Biologics
  • 165. Luina Bio
  • 166. Mabion Poland
  • 167. Maine Biotechnology Services
  • 168. MatriSys Bioscience
  • 169. Medella Naturals
  • 170. Medella Springs Healthcare
  • 171. Menarini Biotech
  • 172. Merck
  • 173. Merck Millipore
  • 174. MeriCal
  • 175. Meridian Life Science
  • 176. MetaboGen
  • 177. Meteoric Biopharmaceuticals
  • 178. Microbax
  • 179. MicroBiopharm Japan
  • 180. Microbiotica
  • 181. Mologic
  • 182. MyBiotics
  • 183. Mycenax Biotech
  • 184. Naked Biome
  • 185. National Cancer Institute (NCI)
  • 186. National Enzyme Company (NEC)
  • 187. National Heart, Lung, and Blood Institute (NHLBI)
  • 188. National Institute of Allergy and Infectious Diseases (NIAID)
  • 189. National Institutes of Health Clinical Center
  • 190. NDB Healthcare
  • 191. Nebraska Cultures
  • 192. New Bellus
  • 193. NIZO
  • 194. Norax Supplements
  • 195. Northway BiotechPharma
  • 196. Novartis
  • 197. Novavax
  • 198. Novo Nordisk
  • 199. NOW Foods
  • 200. NuBiyota
  • 201. NUMAFERM
  • 202. NutraScience Labs
  • 203. Ology Bioservices
  • 204. Olon
  • 205. Orkila
  • 206. Osel
  • 207. OxThera
  • 208. Panacea Biotec
  • 209. Paragon Bioservices (unit of Catalent Biologics)
  • 210. Paras Biopharmaceuticals Finland
  • 211. Pfizer
  • 212. Pfizer CentreOne
  • 213. Pharma-Zentrale
  • 214. Phi Therapeutics
  • 215. Pierre Fabre
  • 216. PiLeJe
  • 217. Polpharma Biologics
  • 218. Polymun Scientific
  • 219. Porton Biopharma
  • 220. Premas Biotech
  • 221. Probi
  • 222. ProbioFerm
  • 223. Probiotic Holdings
  • 224. Probiotical
  • 225. Probiotics Australia
  • 226. Probiotics International
  • 227. Probium
  • 228. Proventus Bioscience
  • 229. Pure Cultures
  • 230. PX'Therapeutics
  • 231. Qu Biologics
  • 232. Quay Pharma
  • 233. Quest Nutra Pharma
  • 234. Quorum Innovations
  • 235. Rebiotix (a subsidiary of Ferring Pharmaceuticals)
  • 236. Retron Probiotics
  • 237. Richter-Helm BioLogics
  • 238. Rise Therapeutics
  • 239. Ritter Pharmaceuticals
  • 240. Roche
  • 241. Sabinsa Europe (a subsidiary of Sami Labs)
  • 242. Sacco
  • 243. Sandoz
  • 244. Sarepta Therapeutics
  • 245. S-Biomedic
  • 246. SciBac
  • 247. Scientific Protein Laboratories
  • 248. Scil Proteins Pharma
  • 249. Scioto Biosciences
  • 250. Second Genome
  • 251. Seed Health
  • 252. Seres Therapeutics
  • 253. SFA Therapeutics
  • 254. SGL Probiotics
  • 255. Siam Bioscience
  • 256. SiliCycle
  • 257. Siolta Therapeutics
  • 258. Sirio Pharma
  • 259. SkinBioTherapeutics
  • 260. Snipr Biome
  • 261. Specialty Enzymes & Probiotics
  • 262. Stelis BioSource™
  • 263. Symberix
  • 264. Symbiotix Biotherapies
  • 265. Syngen Biotech
  • 266. Syngene Interntional
  • 267. Synlogic (acquired by Mirna Therapeutics)
  • 268. Synthetic Biologics
  • 269. Takeda Pharmaceutical
  • 270. TargEDys
  • 271. TARON Solutions
  • 272. Teva Pharmaceutical
  • 273. The Native Antigen
  • 274. Therapure BioPharma
  • 275. Thermo Fisher Scientific
  • 276. THT: probiotics and starter cultures
  • 277. Tokyo Chemical Industry
  • 278. Touchlight Genetics
  • 279. Trayer Biotherapeutics
  • 280. TRU-ID
  • 281. UAS Labs
  • 282. Unique Biotech
  • 283. University of California
  • 284. University of Liverpool
  • 285. University of Oxford
  • 286. University of Pennsylvania
  • 287. University of Pittsburgh
  • 288. Vaiomer
  • 289. Vedanta Biosciences (a subsidiary of PureTech Health)
  • 290. VGXI
  • 291. Virun Nutra-Biosciences
  • 292. VITA-gen Laboratories
  • 293. Vitakem
  • 294. ViThera Pharmaceuticals
  • 295. VxP Biologics
  • 296. WACKER Biotech
  • 297. Waisman Biomanufacturing
  • 298. Washington University School of Medicine
  • 299. Weizmann Institute of Science
  • 300. Winclove Probiotics
  • 301. World Health Organization (WHO)
  • 302. WuXi Biologics
  • 303. Xycrobe Therapeutics (a subsidiary of Crown Laboratories)
  • 304. Yakult Honsha
  • 305. Zeta Farmaceutici
  • 306. Zhejiang Hisun Pharmaceutical
  • 307. Zytex